Rumor mill churning as possible Pfizer/AstraZeneca Round 2 approaches

Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week. And while analysts have been abuzz with the possibilities of a backup bid for Actavis ($ACT) or even GlaxoSmithKline ($GSK), AZ ($AZN) seems to remain the coveted megamerger/tax inversion target that could have the impact Pfizer ($PFE) needs. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.